Covid-19 roundup: Moderna gets the OK to use vaccine in children ages 12-17; 23andMe finds genetic link to loss of taste and smell
Parents in Canada and Europe now have two options to provide their children with a Covid-19 vaccine.
Moderna announced that it has submitted authorization approval for the use of its vaccine in adolescents with both Canadian and EU health officials on Monday. In May, the company announced that the Phase II/III study of the vaccine in children ages 12-17 met its primary endpoints. The jab achieved 100% efficacy in a study that involved 2,500 patients who were observed under the same case definition in the Phase III study in adults.
Unlock this article instantly by becoming a free subscriber.
You’ll get access to free articles each month, plus you can customize what newsletters get delivered to your inbox each week, including breaking news.